Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP).

Full DD Report for AQXP

You must become a subscriber to view this report.


Recent News from (NASDAQ: AQXP)

Aquinox to Present at 2018 UBS Global Healthcare Conference
VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“ Aquinox ”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, anno...
Source: GlobeNewswire
Date: May, 16 2018 13:32
Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan
-Aquinox to Receive $25M in Upfront Payment, Potentially Over $100M in Additional Milestone Payments and Royalties- -Astellas to Obtain Development and Commercialization Rights to Rosiptor, Aquinox’s Lead Drug Candidate, in Japan and Certain Other Countries in...
Source: GlobeNewswire
Date: May, 09 2018 21:00
Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results
VANCOUVER, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a c...
Source: GlobeNewswire
Date: May, 08 2018 09:05
Aquinox Pharmaceuticals (AQXP) Presents At 2018 Bloom Burton & Co. Healthcare Investor Conference - Slideshow
The following slide deck was published by Aquinox Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 04 2018 13:40
Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference
VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“ Aquinox ”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, anno...
Source: GlobeNewswire
Date: May, 02 2018 12:54
Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference
VANCOUVER, British Columbia, April 26, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“ Aquinox ”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, an...
Source: GlobeNewswire
Date: April, 26 2018 09:05
Free Research Report as Zoetis' Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%
Stock Monitor: Aquinox Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free earnings report on Zoetis Inc. (NYSE: ZTS ). If you want access to this report all you need to do is sign up now by clicking the following l...
Source: ACCESSWIRE IA
Date: March, 26 2018 07:30
Aquinox to Present at the 17th Annual Needham Healthcare Conference
VANCOUVER, British Columbia, March 21, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“ Aquinox ”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, an...
Source: GlobeNewswire
Date: March, 21 2018 09:00
Aquinox Pharmaceuticals' (AQXP) CEO David Main on Q4 2017 Results - Earnings Call Transcript
Aquinox Pharmaceuticals, Inc. (AQXP) Q4 2017 Earnings Conference Call March 12, 2018 4:30 PM ET Executives Brendan Payne - Associate Director, Investor Relations David Main - President & Chief Executive Officer Barbara Troupin - Chief Medical Officer & VP, Clinical Develo...
Source: SeekingAlpha
Date: March, 12 2018 21:49
Aquinox Pharma misses by $0.11
Aquinox Pharma (NASDAQ: AQXP ): FY EPS of -$2.14 misses by $0.11 . Cash, cash equivalents, short-term and long-term investments of $108.08M Press Release More news on: Aquinox Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: March, 12 2018 16:12

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1813.2113.0713.3412.97215,916
2018-05-1713.2113.0713.3412.97215,916
2017-06-2014.0014.4914.8913.92120,642
2017-06-1913.4713.9714.3213.47100,179
2017-06-1613.4813.3713.7413.0454,336

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-177,94645,43617.4883Cover
2018-08-1627,858290,3969.5931Cover
2018-08-1540,252235,74917.0741Cover
2018-08-1412,01469,04917.3992Cover
2018-08-1317,050207,8858.2016Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AQXP.


About Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP)

Logo for Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AQXP)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 06 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: March, 26 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: March, 12 2018

       

       


      Daily Technical Chart for (NASDAQ: AQXP)

      Daily Technical Chart for (NASDAQ: AQXP)


      Stay tuned for daily updates and more on (NASDAQ: AQXP)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AQXP)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AQXP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AQXP and does not buy, sell, or trade any shares of AQXP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/